AVR earnings analysis
What we found in AVR's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Anteris delivered Q2 revenue of $1.009 million, up 63% year over year, with gross margin near 76.9% and diluted EPS improving to $(0.30) from $(0.58). However, the operating loss widened 48% to $30.997 million as R&D and SG&A spending increased to support manufacturing scale-up and the PARADIGM Trial. January financing left the company with $260.894 million of cash, cash equivalents and restricted cash, but six-month operating cash burn rose to $49.477 million and management expects substantial losses and additional capital needs. The key positives are clinical-trial expansion and liquidity; the key negatives are regulatory execution, ongoing material weaknesses, and dependence on future financing.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Tissue-product sales grew 63%
- Q2 net sales increased 63% year over year to $1.009 million from $0.618 million, primarily reflecting increased tissue-product sales to 4C. Gross margin was approximately 76.9%, and management said it remained generally consistent with the prior-year period.
- PARADIGM investment accelerated
- The operating loss increased 48% year over year to $30.997 million from $20.884 million, although the operating margin improved to approximately -3,070.1% from -3,378.6% because revenue grew faster than operating expenses. R&D rose 43% to $23.369 million, driven by manufacturing scale-up and PARADIGM Trial activities.
- EPS improved through share issuance
- Diluted loss per share improved to $(0.30) from $(0.58) year over year, despite stockholders’ net loss increasing to $29.094 million from $20.834 million, primarily because weighted-average shares increased to 97.340 million from 36.062 million.
- Clinical program expanded geographically
- PARADIGM recruitment remains ongoing: U.S. enrollment began in May 2026, French recruitment was enabled by June 2026 regulatory clearance, and early clinical experience includes more than 130 patients treated with DurAVR.
- Capital raise materially strengthened liquidity
- Cash, cash equivalents and restricted cash totaled $260.894 million at June 30, 2026 versus $12.576 million at December 31, 2025, following $308.270 million of net share-issuance proceeds. Management believes existing cash and cash equivalents are sufficient for operating requirements for at least the next 12 months.
- Cash burn rose with trial spending
- Six-month operating cash use increased 21% to $49.477 million from $41.024 million, while investing cash use was $0.830 million, including $0.785 million of plant and equipment purchases. A cash-flow-based free cash flow figure was not separately disclosed.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- PMA and trial execution risk
- The company added a supplemental risk that the PARADIGM Trial may be unsuccessful and that FDA PMA may not be obtained or maintained, even though the FDA IDE permits the study to proceed. The trial is intended to support commercialization, and failure could prevent revenue generation or profitability.
- Material weaknesses remain open
- The company reported that disclosure controls and procedures were not effective as of June 30, 2026 because previously identified material weaknesses remained unremediated. The weaknesses involve inadequate procedures and controls and segregation-of-duties deficiencies; remediation testing is ongoing.
- Ongoing funding and dilution risk
- Management expects continued substantial losses and additional funding needs: the six-month operating cash outflow was $49.477 million, accumulated deficit was $422.650 million, and the company states it may be unable to raise additional funds on favorable terms or at all.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.3
- Gross margin
- 76.9%
- Operating margin
- -3070.1%
- Segment
- Single reportable segment: DurAVR THV System and ADAPT products; net sales $1.009 million in Q2 2026 versus $0.618 million in Q2 2025, up 63%. U.S. revenue was $995 thousand, Australia $14 thousand, and Germany $0.
What they said about what is next.
No numeric revenue or EPS guidance was provided. Management expects to continue incurring substantial losses, does not expect significant revenue until regulatory approval and product commercialization, and believes existing cash and cash equivalents will fund operating requirements for at least the next 12 months.
The filing reads about the same as the one before it.
What came before.
- 10-Q · May 12, 2026
- Anteris Technologies reported Q1 2026 revenue of $0.5 million, down 11% from $0.6 million in the previous year, with a decrease largely attributed to the expiration of sales agreements. The company continues to…
- 10-K · February 26, 2026
- Anteris (AVR) remains a development‑stage structural heart company focused on commercializing the DurAVR® THV (a single‑piece, biomimetic valve using ADAPT® anti‑calcification tissue). 2025 operational milestones…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing AVR makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever